Novartis Remibrutinib Hits Both Phase 3 REMODEL Endpoints in MS With No Liver Safety Signal

Novartis (NYSE: NVS) reported positive topline results from both REMODEL-1 and REMODEL-2, its identical Phase 3 trials of oral BTK inhibitor remibrutinib in relapsing multiple sclerosis (RMS). The drug beat teriflunomide on the primary endpoint of annualized relapse rate (ARR) and on every key secondary endpoint, and it did so with no liver safety signal (no cases meeting Hy’s Law criteria) across a development program that now spans more than 4,500 participants. NVS was up roughly 6.0% to about $161 intraday on September 1, from a $152.06 close on August 31 (Finnhub quote; Polygon prior close).

The readout is the first time a BTK inhibitor has delivered Phase 3 efficacy in MS without the hepatotoxicity that has defined the class. Sanofi’s tolebrutinib was rejected by the FDA late last year over drug-induced liver injury risk, and Merck’s evobrutinib was discontinued after liver toxicity. Roche’s fenebrutinib has posted Phase 3 wins in relapsing and primary progressive MS but is still shadowed by safety questions. Remibrutinib’s clean liver profile is the differentiator Novartis has been waiting for.

Both trials randomized roughly 2,000 patients 1:1 to remibrutinib 100 mg or teriflunomide. Beyond the ARR win, remibrutinib showed superiority on key secondary endpoints including MRI lesion counts, a positive trend in 3-month confirmed disability progression, and nominal significance on 6-month confirmed disability progression in a preplanned combined analysis of the two trials. Novartis did not disclose the exact ARR reduction in the topline release; full data come as a late-breaker at MSToronto2026.

Why It Matters

Remibrutinib is already de-risked. The FDA approved the 25 mg dose as Rhapsido for chronic spontaneous urticaria in September 2025, and the EMA followed in April 2026. That means the MS readout is a label expansion for an approved molecule rather than a bet on a wholly unproven drug. MS affects nearly 3 million people worldwide, a far larger market than CSU, and an oral with high efficacy plus a clean liver profile would slot in alongside Novartis’s injectable franchise.

The company plans to submit remibrutinib for RMS to health authorities globally. Novartis said the disability-progression signals and the safety record are what it will lean on to argue for a differentiated benefit-risk profile.

What to Watch Next

The MSToronto2026 late-breaker will show the actual ARR reduction and the disability-progression curves, which decide how strongly remibrutinib stacks up against fenebrutinib and existing oral options. Watch also for the open-label extension and the SPMS program (REMASTER), which would broaden the franchise beyond RMS. On the BTK inhibitor competitive set, see our Biogen BIIB091 coverage.

Novartis press release

What It Means for the Trade

The market gave Novartis about 6% intraday, which is a reasonable-size move for a label expansion — and it reflects that this readout changes the MS competitive map, not just Novartis’s. Every BTK inhibitor in MS has died on liver safety: tolebrutinib rejected, evobrutinib discontinued, fenebrutinib still shadowed. Remibrutinib is the first to clear Phase 3 efficacy with a clean Hy’s Law record across 4,500-plus exposed participants, so it now owns the “oral, high-efficacy, no-hepatotoxicity” lane by itself. That is a positioning asset worth more than the CSU franchise it is layered on.

The timeline matters for sizing. Full data at MSToronto2026 is the next event, and the actual ARR reduction number decides whether this is a blockbuster profile or merely a solid one — “beat teriflunomide” is a low bar that the topline clears without quantifying. Global submissions follow, meaning a potential 2027 approval cadence. In between, the stock has to digest the gap between topline and full curves.

Also note the franchise logic: Novartis already sells Kesimpta, a self-injected anti-CD20 for RMS. An oral BTK with high efficacy and clean liver data doesn’t cannibalize Kesimpta so much as give Novartis both sides of the convenience spectrum — injectable and oral — against Sanofi, Roche, and Biogen as their BTK programs either failed or wait.

Risks and What Could Go Wrong

1. The topline-to-full-data gap. Without a disclosed ARR reduction, the MSToronto2026 presentation could reveal a modest effect that tempers the differentiated benefit-risk argument. This is the single nearest-term risk.
2. Fenebrutinib competition. Roche’s candidate has Phase 3 wins in both relapsing and progressive MS; if its safety record holds up at approval, Novartis loses its “only clean BTK” distinction quickly.
3. Long-duration safety unknowns. A clean Phase 3 liver record does not preclude rare late-emerging signals, and BTK inhibitors in MS are taken for decades — regulators and payers will demand long extension data.
4. Commercial framing risk. If regulators approve with liver-monitoring language despite the clean data, the convenience edge over platform therapies narrows.

Net: the most important MS readout of the year landed in Novartis’s favor. Own the data event, size the gap risk.